One of America’s biggest household brands files for bankruptcy The long-awaited new Qantas plane touches down in soggy Sydney ...

In a breakthrough for incretin medicines, China’s National Medical Products Administration (NMPA) has approved Innovent’s ...

The research and development of new pharmaceuticals is increasingly an international affair, something that recent discussion ...

New rules are reshaping the telehealth market for GLP-1s like Ozempic and Wegovy, potentially impacting access to these drugs ...

There are two ways in which industry can respond to the GLP-1 craze. On the one hand, they can, like Nestlé, create smaller ...

Three people share the hoops they've jumped through, financial strain they've endured and risks they've taken on in order to ...

Due to popularity of the medications, GLP-1s were in short supply up until recently. Obesity is a common issue among ...

Another major insurance change coming next year will affect another large swath of Dushay’s patients: In January, BCBS ...

Novo Nordisk cut ties with Hims & Hers, accusing the telehealth firm of promoting Wegovy copycat versions of the weight-loss ...

Earlier this week, the pharma giant publicly accused Hims & Hers of “deceptive” marketing that is putting patient safety at risk.

The Delhi High Court has instructed India's drug regulator to address concerns about the approval process for drugs like ...

Price differences are especially pertinent with these weight loss drugs, which are officially called glucagon-like peptide-1 receptor agonists (GLP-1RA), due to the emergence of compounded ...